Neuropace Inc (NPCE) - Total Assets
Based on the latest financial reports, Neuropace Inc (NPCE) holds total assets worth $96.99 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neuropace Inc - Total Assets Trend (2019–2025)
This chart illustrates how Neuropace Inc's total assets have evolved over time, based on quarterly financial data. Also see Neuropace Inc (NPCE) market capitalisation for the company's overall valuation and market capitalisation.
Neuropace Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Neuropace Inc's total assets of $96.99 Million consist of 89.1% current assets and 10.9% non-current assets. Review Neuropace Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.6% |
| Accounts Receivable | $14.68 Million | 13.9% |
| Inventory | $16.90 Million | 16.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Neuropace Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Neuropace Inc (NPCE) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuropace Inc's current assets represent 89.1% of total assets in 2025, a decrease from 96.0% in 2019.
- Cash Position: Cash and equivalents constituted 20.6% of total assets in 2025, up from 19.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 16.0% of total assets.
Neuropace Inc Competitors by Total Assets
Key competitors of Neuropace Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Neuropace Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.94 | 5.47 | 16.20 |
| Quick Ratio | 3.91 | 4.51 | 15.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $68.76 Million | $76.60 Million | $131.82 Million |
Neuropace Inc - Advanced Valuation Insights
This section examines the relationship between Neuropace Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 42.61 |
| Latest Market Cap to Assets Ratio | 4.60 |
| Asset Growth Rate (YoY) | 11.5% |
| Total Assets | $105.56 Million |
| Market Capitalization | $485.69 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neuropace Inc's assets at a significant premium (4.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neuropace Inc's assets grew by 11.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuropace Inc (2019–2025)
The table below shows the annual total assets of Neuropace Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $105.56 Million | +11.54% |
| 2024-12-31 | $94.65 Million | -12.08% |
| 2023-12-31 | $107.65 Million | -5.66% |
| 2022-12-31 | $114.11 Million | -14.57% |
| 2021-12-31 | $133.56 Million | +138.72% |
| 2020-12-31 | $55.95 Million | +165.23% |
| 2019-12-31 | $21.09 Million | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more